When Will Orforglipron Be Available? The Realistic Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• Orforglipron remains investigational as of May 2026 and is not commercially available
• Eli Lilly indicated it would file an NDA with the FDA in 2025 following the ACHIEVE-1 phase 3 readout in April 2025
• If filed in late 2025, a regulatory decision is plausible in the second half of 2026, though not guaranteed
• The obesity indication (ATTAIN program) will likely follow or run alongside the diabetes indication
• FormBlends has no path to dispense orforglipron and recommends working with your clinician on currently available options rather than waiting indefinitely

Direct answer

Orforglipron is not yet available. Eli Lilly stated it would submit a New Drug Application to the FDA in 2025 based on positive ACHIEVE-1 and ATTAIN-1 phase 3 results. A standard FDA review runs 10 to 12 months, so a regulatory decision is plausible by late 2026. Commercial launch typically begins within weeks of approval. Patients should verify current FDA status before making clinical decisions, because dates can slip and have slipped for other drugs in this class.

Table of contents

1. Where orforglipron stands today
2. The ACHIEVE-1 readout and what it triggered
3. How the FDA review process works for new drugs
4. The realistic launch scenarios
5. Why timelines slip and what could push approval later
6. Diabetes first or obesity first
7. What launch availability actually looks like
8. The cost question if you wait
9. The contrary view: waiting can make medical sense
10. Decision framework if you are weighing the wait
11. FAQ
12. Sources

Where orforglipron stands today

Orforglipron is an investigational once-daily oral GLP-1 receptor agonist developed by Eli Lilly. As of May 2026, it is in late-stage clinical development. Phase 3 trials in both type 2 diabetes (the ACHIEVE program) and obesity (the ATTAIN program) have reported positive primary results.

Lilly publicly indicated, following the April 2025 ACHIEVE-1 readout, that it intended to file a New Drug Application with the U.S. Food and Drug Administration in 2025. Whether that filing has been formally received and accepted by the FDA, and which review pathway the agency assigns, are facts that can change between this article being written and when you read it. Always confirm current status with the FDA's drug approval database or current Lilly investor communications.

Outside the United States, orforglipron is also under regulatory review in Japan, Europe, and other major markets. The Japanese review is of particular interest because of the original Chugai discovery and the Japan-specific timing dynamics that have applied to other oral diabetes drugs.

The ACHIEVE-1 readout and what it triggered

The ACHIEVE-1 trial randomized adults with type 2 diabetes to placebo or one of three orforglipron doses (3 mg, 12 mg, or 36 mg daily) for 72 weeks. The results, reported April 17, 2025:

• Mean HbA1c reduction at 36 mg: approximately 1.3-1.6 percentage points
• Mean weight loss at 36 mg: approximately 14.7%
• Safety profile consistent with the GLP-1 class (mainly GI side effects)

The readout was the cleanest data point Lilly needed to proceed with an FDA submission. It cleared the efficacy bar for diabetes (HbA1c reduction is the primary FDA endpoint for type 2 diabetes drugs) and produced weight loss numbers consistent with phase 2 expectations. ATTAIN-1, the parallel obesity trial, reported positive results in 2025 as well, supporting a separate or combined obesity application.

Once a sponsor has positive phase 3 data, the path to FDA submission typically takes several months. The sponsor needs to complete the long-term safety analyses, finalize the chemistry-manufacturing-controls section, prepare the proposed labeling, and integrate all of this into the NDA package. For a drug with multiple phase 3 trials, this preparation can stretch six to nine months from the headline readout to formal submission.

How the FDA review process works for new drugs

Understanding the FDA process helps set realistic expectations.

Step	Typical duration	What happens
NDA submission	Day 0	Sponsor submits the full data package
FDA filing review	~60 days	FDA confirms the application is complete enough to review
Standard review	10 months from filing acceptance	FDA reviews efficacy, safety, manufacturing
Priority review (if granted)	6 months from filing acceptance	Used for drugs offering significant improvement; not guaranteed
Advisory committee meeting	If convened, adds 1-2 months	External experts review and vote on approval recommendation
PDUFA date	Target decision date	FDA aims to issue an approval, complete response letter, or extension
Commercial launch	2-12 weeks after approval	Sponsor ships product to wholesalers and pharmacies

The Prescription Drug User Fee Act (PDUFA) sets the target decision date. For standard review, that target is 10 months after the FDA accepts the filing. For priority review, it is 6 months. Orforglipron is unlikely to receive priority review because it would not be the first-in-class drug for an unmet need; multiple effective GLP-1 medications already exist. Standard review is the more likely pathway.

If Lilly's NDA was submitted in mid-to-late 2025, filing acceptance would land in late 2025 or early 2026, and the PDUFA date would fall in late 2026. That is the scenario most consistent with current public information. Earlier or later submissions shift the entire window.

The realistic launch scenarios

Three scenarios cover most of the probability space.

Best case: late 2026 approval, launch in Q4 2026 or Q1 2027. This assumes a clean review with no major hurdles, no advisory committee meeting, and approval at or near the PDUFA date. Lilly has manufacturing capacity in place to support launch volumes. Initial supply may be allocated, similar to early Zepbound launch dynamics.

Middle case: mid-2027 approval. The FDA can extend the review by three months for major amendments to the application. An advisory committee meeting can add additional time. A complete response letter (a request for more information rather than approval) could push the timeline by months or longer, depending on what is asked.

Worst case: 2028 or later. Safety findings during review (particularly hepatic, pancreatic, or thyroid signals) can require additional studies. Manufacturing inspection failures can delay approval until corrected. Changes in FDA leadership or policy priorities can affect drug-class-wide review timing.

For planning purposes, the middle scenario is the most defensible base case. Patients who urgently need treatment should not plan around the best case.

Why timelines slip and what could push approval later

Several factors typically delay drug approvals:

Hepatic safety signals. Orforglipron phase 2 data showed small, reversible elevations in liver enzymes at higher doses. The FDA scrutinizes liver findings carefully for chronic-use drugs, especially in a market segment where patients may be on therapy for years. A request for additional liver-focused analyses could extend the review.

Manufacturing inspections. The FDA must inspect the manufacturing facility before approval. Findings during inspection can require remediation. Lilly has multiple manufacturing sites for tirzepatide, so the company has experience with this process, but each new product has its own inspection cycle.

Advisory committee meeting. The FDA can convene an advisory committee of external experts to advise on approval decisions for novel drugs. While orforglipron is not first-in-class, the small-molecule oral GLP-1 mechanism is new enough that an advisory meeting is possible. These meetings add weeks to months to the timeline.

Pediatric studies, post-marketing commitment negotiations, REMS (Risk Evaluation and Mitigation Strategy) requirements, and labeling negotiations can each add time. Most of these adjustments happen behind the scenes and do not push the PDUFA date significantly, but they can move the launch date.

Diabetes first or obesity first

Lilly's commercial pattern with tirzepatide suggests how orforglipron will roll out.

Tirzepatide was approved as Mounjaro for type 2 diabetes in May 2022, then as Zepbound for chronic weight management in November 2023, a gap of 18 months. The two indications used overlapping but separate NDAs and separate brand names because of pricing and marketing strategy reasons.

Orforglipron may follow the same playbook: diabetes approval first under one brand, obesity approval later under a second brand. The ACHIEVE phase 3 program supports diabetes; the ATTAIN program supports obesity. Whether Lilly submits both indications simultaneously or sequentially is a strategic choice.

The faster route would be a single NDA combining diabetes and obesity data. The historical pattern in this class has been separate NDAs, partly because the FDA reviews are run by different divisions (the Division of Diabetes, Lipid Disorders, and Obesity reviews both, but the trial design and endpoints differ). Patients should not assume same-day availability for both indications.

What launch availability actually looks like

Even after FDA approval, getting a prescription filled is not automatic. The Zepbound launch in late 2023 provides a relevant comparison:

• FDA approval: November 8, 2023
• Commercial availability: early December 2023 in limited supply
• National rollout: gradual through 2024
• Insurance coverage decisions: trickled in through 2024-2025

Orforglipron has an advantage on the supply side: small molecules are easier to manufacture at scale than peptides. Lilly's manufacturing constraints with tirzepatide were a peptide-specific problem. Tablets can be produced in higher volumes more quickly. This may mean fewer supply shortages at launch.

The disadvantage on the patient side is insurance coverage. New branded medications typically have low formulary coverage in their first 12-18 months on market. Most patients face high out-of-pocket costs at launch ($800-$1,200/month is a plausible range for an oral GLP-1) until coverage expands. Lilly's commercial cards and direct-pay programs may help some patients, similar to the LillyDirect program for Zepbound.

The cost question if you wait

Waiting for orforglipron is not financially free.

An obese patient (BMI 30+) accumulates cardiovascular and metabolic risk while untreated. The DiRECT trial (Lean et al., The Lancet 2018) and the Look AHEAD trial (Look AHEAD Research Group, NEJM 2013) document the dose-response between sustained weight loss and reduced incidence of type 2 diabetes, hypertension, and obstructive sleep apnea. Each year of untreated obesity carries measurable health cost.

For a patient with current BMI in the obese range:

• 12 months of untreated obesity: roughly 2-3% additional incidence of new metabolic complications
• 24 months of untreated obesity: complications begin to compound

The expected wait for orforglipron approval and accessible launch pricing is likely 12-24 months from the writing of this article. The patient considering whether to wait should compare that 12-24 month interval against the option of starting an FDA-approved or 503A-compounded option now.

If the only barrier to therapy is needle aversion, the wait is rational. If the patient would otherwise initiate semaglutide or tirzepatide today, waiting is harder to justify medically.

The contrary view: waiting can make medical sense

The strongest case for waiting is built around the patient who would not start any injectable therapy under any circumstances.

Surveys of patients who decline GLP-1 therapy consistently identify needle aversion, daily friction with injection prep, and storage concerns as primary barriers. These patients are not making an irrational choice. The marginal benefit of starting a therapy you will not continue is small; the marginal cost (side effects, expense, regimen friction) is real. For this patient, waiting for an oral option is medically appropriate.

A second case for waiting: patients with mild obesity (BMI 30-32, no comorbidities) where the medical urgency is low. The expected complication rate over a 12-24 month wait is small, and the available data on long-term safety of GLP-1 therapy is still maturing. Waiting buys more safety data and lower regret risk.

A third case: patients with strong cost sensitivity who expect cheaper oral options to drive overall category pricing down. This is speculative. The historical pattern in GLP-1 pricing has been parity rather than competition-driven price cuts. The compounded market has produced more cost relief than oral entry, and compounded orforglipron is unlikely.

Decision framework if you are weighing the wait

Use the following questions to organize the choice.

Is your BMI in the moderate-to-severe obese range (BMI 32+) or do you have a major obesity-related comorbidity? If yes, the cost of waiting is higher. Starting therapy now and possibly switching later is generally the better choice.

Have you already tried and failed dietary intervention for at least 6 months? If yes, the marginal value of more time on lifestyle-only intervention is low. Earlier therapy reduces cumulative health burden.

Is needle aversion your primary reason for not starting? If yes, waiting for orforglipron is reasonable, but build a contingency plan in case approval slips. Discuss bridging options with your clinician.

If you have strong needle aversion but moderate-to-severe metabolic risk: the right answer is usually to start injectable therapy now, with the option to switch when orforglipron becomes available. Many patients overcome injection anxiety within the first 2-3 weeks of therapy.

If you have mild BMI and no comorbidities: waiting is medically defensible. Use the waiting period to optimize nutrition, sleep, and resistance training, all of which improve outcomes when therapy starts.

FAQ

When will orforglipron be available?

Eli Lilly indicated it would file with the FDA in 2025 based on the ACHIEVE-1 (diabetes) and ATTAIN-1 (obesity) phase 3 results. A standard FDA review takes roughly 10-12 months. If the filing went in by late 2025, a regulatory decision is possible in late 2026. Commercial launch typically follows approval within 1-3 months. As of May 2026, orforglipron is not yet FDA-approved.

Has Lilly filed orforglipron with the FDA?

Lilly publicly stated it intended to submit a New Drug Application (NDA) to the FDA for orforglipron in 2025 following the ACHIEVE-1 phase 3 readout. Check current FDA filings, Lilly press releases, and the FDA's drug approval calendar for the most recent confirmation.

When will orforglipron launch for weight loss?

The weight-loss indication will likely follow the diabetes indication. ATTAIN-1, the phase 3 trial in obesity without diabetes, was positive. A separate NDA or supplemental NDA for the obesity indication is expected. Wegovy followed Ozempic by about four years; orforglipron's two indications are likely to launch closer together because both phase 3 programs ran in parallel.

Will orforglipron be available in 2026?

Possibly, but not guaranteed. If Lilly's filing went in by late 2025 and the FDA grants standard review with no major issues, approval in the second half of 2026 is plausible. Commercial launch could begin shortly after. Priority review, advisory committee meetings, or manufacturing inspections could push the timeline later.

Can I get orforglipron right now?

Not legally in the United States. Orforglipron is investigational and only available through participation in a clinical trial. Some patients seek it through gray-market international suppliers; this is unsafe, illegal in many jurisdictions, and carries no quality assurance. FormBlends does not sell or supply orforglipron.

Should I wait for orforglipron or start tirzepatide now?

For most patients with obesity, starting an FDA-approved or 503A-compounded option now and possibly switching later is the better risk-adjusted strategy. Untreated obesity carries cumulative cardiovascular and metabolic risk. Tirzepatide currently produces greater mean weight loss than orforglipron in the available trial data. Discuss the trade-off with your clinician.

Will there be a generic or compounded version of orforglipron?

Generic versions cannot enter the market until patents expire and the FDA approves an Abbreviated New Drug Application (ANDA), which is typically 10-20 years after launch. Compounded versions through 503A pharmacies are unlikely because small-molecule oral drugs do not enter the FDA shortage list pathway that has enabled compounded semaglutide and tirzepatide.

Related guides

• When Will Retatrutide Be Available? A Realistic Timeline
• When Will CagriSema Be Available? Reading the FDA Timeline Honestly
• Retatrutide FDA Approval Timeline: When Will It Be Available?
• Orforglipron vs Zepbound: A Realistic Side-by-Side
• How Much Will Orforglipron Cost? The Pricing Outlook
• When Will Retatrutide Be Available? The Four Meanings of "Available" in May 2026
• Tool: weight-loss timeline tool

Sources

1. Eli Lilly and Company. ACHIEVE-1 Phase 3 results, press release. April 17, 2025.
2. Eli Lilly and Company. ATTAIN-1 Phase 3 results, press release. 2025.
3. U.S. Food and Drug Administration. New Drug Application (NDA) process and PDUFA timelines. FDA.gov. Reviewed 2024.
4. U.S. Food and Drug Administration. Mounjaro (tirzepatide) approval letter. May 13, 2022.
5. U.S. Food and Drug Administration. Zepbound (tirzepatide) approval letter. November 8, 2023.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002.
7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.
8. Saxena AR, Frias JP, Brown LS, et al. Phase 2 results of orforglipron. The Lancet. 2023;401:1881-1891.
9. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). The Lancet. 2018;391:541-551.
10. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine. 2013;369:145-154.
11. FDA Drugs@FDA database. Approval status verification. fda.gov.

Footer disclaimers

Platform Disclaimer. FormBlends provides clinician-supervised weight management with FDA-approved and 503A-compounded GLP-1 medications. This article is informational. Orforglipron remains investigational. FormBlends does not prescribe, dispense, compound, or accept orders for orforglipron, and we have no commercial arrangement with Eli Lilly.

Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are prepared by 503A pharmacies under individual prescription. These products are not FDA-approved and are not therapeutically interchangeable with brand-name products. Orforglipron cannot be compounded because small-molecule oral drugs are not eligible for the 503A pathway used for peptide shortages.

Results Disclaimer. Phase 3 trial averages do not predict individual results. Long-term weight maintenance depends on sustained therapy and continued behavior change. Speculative timelines in this article are estimates, not commitments.

Trademark Notice. Orforglipron is the development name of an investigational drug owned by Eli Lilly and Company. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends has no affiliation with Eli Lilly or Novo Nordisk.